Lunit to highlight AI biomarker platform at ASCO meeting
SaveSavedRemoved 0
[ad_1]
Of particular note will be a study the company conducted with the Japan National Cancer Center East (NCCE), which investigated microsatellite stable locally advanced rectal cancer with the firm’s Lunit SCOPE IO, an AI-powered tumor-infiltrating lymphocyte (TIL) analyzer.
The research measured tumor-infiltrating lymphocyte density during chemoradiotherapy and found a link between the change in TIL density and the pathologic complete response rate, according to Lunit.
Copyright © 2023 AuntMinnie.com
[ad_2]
Go to publisher site for the complete article:
Read More
